Akoun G, Battesti J P, Bignon J, Caubarrere I, Charpin J, Chicou J F, Godard P, Herman D M, Julien D, Michel F B
Poumon Coeur. 1983;39(6):333-6.
In a co-operative study involving 10 centres, 95 asthmatic patients were treated with Armophylline, a new slow-release theophylline for a period of 1 to 3 months. Eighty per cent of the patients receiving the drug in doses of 11 to 15 mg/kg/day immediately had adequate blood theophylline levels (7-20 mcg/ml). There was a significant decrease in dyspnoea and number of asthmatic attacks and a significant increase in FEV1 and FEV1/VC ratio. The drug was usually well tolerated. Side-effects, such as insomnia, headache or digestive disorders were, as a rule, mild.
在一项涉及10个中心的合作研究中，95名哮喘患者接受了一种新型缓释茶碱——氨茶碱的治疗，为期1至3个月。80%接受剂量为11至15毫克/千克/天药物治疗的患者，其血液中的茶碱水平立即达到了足够的水平（7 - 20微克/毫升）。呼吸困难和哮喘发作次数显著减少，第一秒用力呼气容积（FEV1）和FEV1/肺活量（VC）比值显著增加。该药物通常耐受性良好。副作用，如失眠、头痛或消化系统紊乱，通常较为轻微。
